Comparison · NCT00003641-sae
Observation vs Interferon Alfa-2b: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Observation vs Interferon Alfa-2b: serious adverse events. Trial comparisons, record NCT00003641-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00003641-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0456 | 0.0297 | 0.0693 | wilson | |
| Risk in group 2 | 0.572 | 0.531 | 0.612 | wilson | |
| Risk difference, group 1 minus group 2 | -0.527 | -0.57 | -0.479 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.0796 | 0.0516 | 0.123 | log | |
| Odds ratio, group 1 over group 2 | 0.0357 | 0.0221 | 0.0576 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Observation than on Interferon Alfa-2b | 1.9 | 1.76 | 2.09 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Observation | Patients undergo observation for 4 weeks | 20 | 439 | EG000 |
| Group 2 | Interferon Alfa-2b | Patients receive high-dose interferon alfa-2b IV over 20 minutes daily for 5 consecutive days | 325 | 568 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Assessed at the end of treatment (4 weeks) and for 30 days following the last dose of protocol drug, or until the initiation of subsequent treatment, whichever comes first
Source ClinicalTrials.gov
Trial
- Title
- High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma
- NCT number
- NCT00003641
- Phases
- PHASE3
- Conditions
- Melanoma (Skin)
- Interventions
- interferon alfa-2b, observation
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Results first posted
- 2016-05-04
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00003641?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00003641-sae